[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621998":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":16,"centralContacts":36,"locations":16,"responsibleParty":47,"collaborators":16,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":16,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":16,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":16,"overallStatus":71,"whyStopped":16,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":77,"leadSponsor":79,"locationsCount":16},{"fullName":5,"class":6},"Sohag University","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Mg sulphate group","EXPERIMENTAL","50 mg\u002Fkg magnesium sulphate diluted in 100 mL of normal saline.",[13],"Drug: Mg (magnesium sulfate)",{"label":15,"type":10,"description":16,"interventionNames":17},"dexmedetomidine group",null,[18],"Drug: Dexmedetomidin",{"label":20,"type":10,"description":16,"interventionNames":21},"ondansetron group",[22],"Drug: Ondansetron 8 mg",[24,29,32],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":16},"DRUG","Dexmedetomidin","•Group D (Dexmedetomidine Group): 0.5 µg\u002Fkg dexmedetomidine diluted in 100 mL of normal saline.",[15],{"type":25,"name":30,"description":11,"armGroupLabels":31,"otherNames":16},"Mg (magnesium sulfate)",[9],{"type":25,"name":33,"description":34,"armGroupLabels":35,"otherNames":16},"Ondansetron 8 mg","8 mg ondansetron diluted in 100 mL of normal saline.",[20],[37,43],{"name":38,"role":39,"phone":40,"phoneExt":41,"email":42},"Aya Mohammed Aboelwafa, Resident of anesthesia","CONTACT","01095848062","01002181828","aya_muhammad_post@med.sohag.edu.eg",{"name":44,"role":39,"phone":45,"phoneExt":40,"email":46},"Ahmed Elsaied Abd Elrahman, Professor","01118011611","elsaiedsoon@gmail.com",{"type":48,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":16,"oldOrganization":16},"PRINCIPAL_INVESTIGATOR","Aya Muhammad Aboelwafa","Resident of anesthesia and surgical intensive care unit and pain management","100621998","post-operative-shivering-following-anesthesia-100621998",false,"NCT07377903","Post Operative Shivering Following Anesthesia","Pharmacological Management of Post Operative Shivering Following Anesthesia","Inclusion Criteria:\n\n* Age from 18 to 45 years.\n* Both sexes.\n* American Society of Anesthesiologists physical status I, II\n* Scheduled for elective lower abdominal or lower limb surgeries under spinal anesthesia\n\nExclusion Criteria:\n\n* Patients with known allergy to study drugs.\n* Patients with baseline body temperature outside the normal range (36-37.5°C).\n* History of thermoregulatory disorders, thyroid dysfunction, or neurological diseases.\n* Patients receive sedatives, antipsychotics, or antidepressants.\n* Patients require intraoperative conversion to general anesthesia.",true,"ALL","18 Years","45 Years",{"count":63,"type":64},60,"ESTIMATED","INTERVENTIONAL",[67],"NA","The aim of this study is to compare the efficacy of magnesium sulphate, ondansetron, and dexmedetomidine in managing post-spinal anesthesia shivering. The primary aim is the time to cessation of shivering after drug administration, while secondary aim include hemodynamic parameters (heart rate, blood pressure, SpO₂ ) and the recurrence of shivering",[70],"Shivering, Spinal Anesthesia","NOT_YET_RECRUITING","2026-02-01",{"date":74,"type":75},"2026-02-04","ACTUAL",{"date":72,"type":64},{"date":78,"type":64},"2026-09-01",{"name":5,"class":6}]